LeMaitre resumed with a Buy at Roth Capital

Roth Capital resumed coverage of LeMaitre (LMAT) with a Buy rating and $108 price target The firm says the company’s product portfolio vascular surgeons combined with its direct sales force of 164 reps is driving organic sales growth of 15% with favorable operating leverage. It sees upcoming catalysts for LeMaitre from RestoreFlow approvals in Ireland and Germany as well as the XenoSure vascular patch regulatory submission in China.